As marijuana markets open, tracking key transaction information is important for public health and economic analysis. Washington State's seed-to-sale database appears to have had little oversight and non-standard reporting, leading to a database less promising than its potential should allow for measuring cannabinoid levels and relating potency to price. Documenting and studying the dynamics of legal marijuana markets in terms of product types and cannabinoid availability are important additions to this emerging policy area. Smart et al. 1 provide a valuable report on how the Washington state market has moved towards higher potency products. Putting aside whether this violates the Iron Law of Prohibition, or questions of model specification or over-powered analysis, we wish to draw attention to the need for better data. Imagine how much stronger the conclusions of Smart et al. might have been without measurement error in both potency and price, and with the ability to analyze across product types. Our experience with these same data has revealed numerous problems with the potency results, some of which are hinted at in Smart et al., as when they note that: ‘unlike with edibles, their [usable marijuana and extracts for inhalation] potency characteristics are readily retrievable from the traceability data’ (p. 2). The database has fields for Total tetrahydrocannabinol (THC), THC, tetrahydrocannabinolic acid (THC-A) and cannabidiol (CBD) potency results. Our experience has shown idiosyncratic use of these fields by those inputting the traceability data as mandated by the state Liquor and Cannabis Board (LCB). Some appear to ignore the Total THC field, some simply repeat the THC result and some provide the sum of THC and CBD or (possibly) of all cannabinoids. Data problems include: potency profiles with minimal CBD reported in which Total THC and/or THC are less than 1 (perhaps reporting a proportion); edibles listed at 80 or more for either THC or CBD, which appears to be the total milligrams for the 10-pack; and topicals described as ‘5 ampules—300 mg’ where the total THC is 68.8 or 93.1. The inconsistencies within potency results and between potency and marketing are troubling. There appears to be no guidance from the LCB as to how to report potencies, and so we are left to guess whether small values are proportions, results are for a single serving or the whole package and results for liquids are in milligrams, percentage by weight or percentage by volume. (We should note that the LCB announced recently that the tracking database is going to be revised with a new vendor.) This is why Smart et al. smartly apply the formula Total THC = THC + .877 × THC-A to all observations before analysis, drop observations with adjusted Total THC of 0 or greater than 100%, and swiftly drop all product types but usable marijuana, apparently concluding that even the concentrates are problematic. This may be borne out in their histograms of potency, which appear to indicate very low potency concentrates. While limiting potencies to the range of 0–100 eliminates clearly impossible results, the idiosyncratic entry of the potency fields means the remaining data are measured with some unknown level of error. We have seen similar inconsistency in the pricing field, RetailPrice: some appear to report the per-package price before any discounts, while most assume this is the total amount paid for all similar packages in that transaction. Within the usable marijuana category, this amounts to measurement error in potency and perhaps price, which lowers the power of any analysis regressing one on the other. A full analysis of how recreational users might be moving to more potent forms of marijuana and the price elasticity of potency, however, would require having comparably valid data on the prices and potencies of all forms of marijuana. Our experience, and the analytical choices of Smart and colleagues, reveal that the vast Washington state seed-to-sale database does not contain the requisite data. There are fields that might collect these data, but currently those fields are mostly useless. We hope that Washington, and any other states with comparable data systems, will collect clear, accurate and useful data in the future. Contributions of J.R.W and C.B-G. funded in part by the Washington State Dedicated Marijuana Fund for research at the University of Washington, sourced from marijuana excise taxes. C.B-G. and D.A.B. funded in part by NIH/NIDA R03DA038806. D.A.B. is a paid consultant for Mathematica Policy Research on a study of marijuana use funded by the Massachusetts Department of Public Health. None.
Read full abstract